Navigation Links
ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
Date:7/8/2008

ca (IDSA) expressing concerns of infectious disease experts. A copy of ViroPharma's letter and the attachment is now available on ViroPharma's website at http://www.viropharma.com/OGDpetition/.

FDA has indicated that ViroPharma can expect the opportunity for public input regarding bioequivalence methods for Vancocin, but has not yet committed to a next step. Commented Colin Broom, M.D., ViroPharma's vice president, chief scientific officer, "We are encouraged that FDA appears to be taking the first step toward a public process to consider the development of bioequivalence methods for locally acting drugs that treat gastrointestinal conditions. After the general discussion at the July 23rd Advisory Committee meeting, FDA should be better prepared to conduct a public process on bioequivalence methods for Vancocin specifically. ViroPharma is prepared to participate in that process when the time comes. We have long contended that changes in GI physiology observed in patients with Clostridium difficile infection make healthy gut bioequivalence models inapplicable to drugs, like Vancocin, which treat this condition."

ViroPharma has previously explained in various submissions to FDA that appropriate public process for development of bioequivalence methods specifically for Vancocin should include (1) public proposal of the method and the data FDA believes validate that method; (2) FDA receipt of and response to public comments on the proposed method; (3) consideration by the appropriate FDA Advisory Committees, including the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; and (4) final decision making on whether to adopt the method by neutral scientific and medical experts, not the FDA personnel who originally proposed the method. ViroPharma continues to believe that bioequivalence for Vancocin is deserving of at least the same level of process and scientific discussion
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
2. ViroPharma to Present at Two Upcoming Healthcare Conferences
3. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
4. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
7. ViroPharma to Present at the BIO CEO & Investor Conference
8. ViroPharma Provides 2008 Outlook
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. Vasogen Provides Corporate Update
11. Culligan's New Aqua-Cleer Advanced Drinking Water SystemProvides Clean, Quality Water Customized for Every Home
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... LOUIS (PRWEB) , ... August 03, 2015 , ... Nine ... in Iowa, Illinois and Indiana. Hosted by the Soil Health Partnership , the ... create lasting environmental benefits while potentially increasing farm productivity and income. , Brent Bible ...
(Date:8/3/2015)... -- According to a new market report ... Asia to Witness Highest Growth by ... culture market was valued at US$ 586.1 Mn in 2014 ... 29.1% to account for US$ 2,717.6 Mn by 2020. ... 3D cell culture refers to a process ...
(Date:7/31/2015)... Texas (PRWEB) , ... July 31, 2015 , ... ... report, offering competitive market analysis and premium industry insights on the global resorcinol ... based on a collective study of vivid market scenarios and analysis of primary ...
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
Breaking Biology Technology:Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4
... YORK, Aug. 17, 2011 Hadasit Bio-Holdings, Ltd. - ... all based on intellectual property developed by the Hadassah ... its portfolio company Enlivex Therapeutics (92% owned by Hadasit ... four groups in its Phase I / II clinical ...
... UAE, August 17, 2011 Global pharmaceutical ... trials due to the increase in drug development costs ... The Middle East is forecasted to be one of ... on availability of the required infrastructure, access to necessary ...
... 17, 2011 PAREXEL International Corporation (NASDAQ: ... been named Company of the Year for the Pharmaceutical ... only global, all-encompassing business awards program honoring great performances ... its global client base increase the efficiency of clinical ...
Cached Biology Technology:Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 2Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 3Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 4Middle East to be the Future in Clincial Trials 2PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 2PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 3PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 4PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 5
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/23/2015)... 23, 2015 Research and Markets ( ... "Global Outlook of the Biometrics Industry 2015 ... The global biometrics market is likely to ... applications owing to the uptake of multiple technologies ... that enhances the growth of biometrics in existing ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... a scientific detective story that uncovers a previously ... class of air pollutants. Incardona of the ... scientists from the U.S. government, Canadian government and ... to Ocean Basins: Emerging Chemical Contaminants and Human ...
... Feb. 15 The U.S. Department of ... begun collecting additional,fingerprints from international visitors arriving ... part of the department,s upgrade from two-,to ... legitimate,travel by more accurately and efficiently establishing ...
... tuna nets are a heart-wrenching reminder of the impact ... as by-catch, this killing of non-target species is a ... possible solution, advanced by NSERC grantee Dr. Suzana Dragicevic ... digital maps and mathematical analysis to visualize and better ...
Cached Biology News:DHS Begins Collecting 10 Fingerprints From International Visitors at Orlando International Airport 2New tool for resolving fisheries conflicts 2
XPMC2H Immunogen: XPMC2H (NP_065118, 323 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Ideally suited for resolving DNA and RNA 10-1000 bases especially PCR products ranging from 100-1000 bp. Gelling temp. (4%) 27C Melting temperature 65C. EEO: 0.10 Rnase/Dnase: none detected...
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
...
Biology Products: